ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Doxycycline Hyclate Tablets USP, 75 mg and 150 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate of the Company has been reported as lost/misplaced and the legal heirs of the registered shareholder of such lost share certificate have requested the Company for issue of duplicate share certificate for the purpose of claiming those shares from the Investor Education and Protection Fund (IEPF). We enclose herewith a letter received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Closure of Trading Window
With reference to the captioned matter, this is to inform the exchange that in terms of the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company will remain closed from 1st July, 2020 till further advice. The date of the Board Meeting for inter alia considering the unaudited financial results for the quarter ended 30th June, 2020 and the date of re-opening of trading window will be intimated in due course. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificates published by the Company on behalf of the registered shareholder(s) in English language newspaper - Business Standard on 24th June, 2020. We request you to kindly take the same on record.
Buy Alembic Pharma; target of Rs 1100: YES Securities
YES Securities is bullish on Alembic Pharma has recommended buy rating on the stock with a target price of Rs 1100 in its research report dated June 15, 2020. Alembic Pharma share hits all-time high on USFDA nod for Rivaroxaban tablets
Alembic Pharmaceuticals said it received tentative approval for its generic version of Rivaroxaban tablets, which is used in the treatment of embolism and deep vein thrombosis ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Rivaroxaban Tablets, 10 mg, 15 mg, and 20 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record. Alembic Pharma gets USFDA nod for generic Adapalene gel for acne treatment
The product was indicated for the topical treatment of acne vulgaris in patients 12 years of age and older, Alembic Pharma said ALEMBIC PHARMACEUTICALS LTD. - 533573 - Alembic Pharmaceuticals Limited Receives Establishment Inspection Report (EIR) For Its General Oral Solid Formulation Facility (F-I) At Panelav
We would like to inform the exchange that the Company has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out by them at our General Oral Solid Formulation Facility (F-I) at Panelav during the period from 9th March, 2020 to 13th March, 2020. With this, EIR is in place for all our manufacturing facilities for international markets. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company's joint venture, Aleor Dermaceuticals Limited, has received US Food and Drug Administration (USFDA) Final Approval for Adapalene Gel USP, 0.3%. Please find enclosed herewith our press release. We request you to kindly take the same on record.